Teva Pharmaceutical Industries LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Migdal Insurance & Financial Holdings Ltd. has reported a beneficial ownership of 5.37% in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.
NYSE
Harel Insurance Investments & Financial Services Ltd. has reported a 6.3% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.
NYSE
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of September 30, 2025.
NYSE
Harel Insurance Investments & Financial Services Ltd has reported a 5.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd, primarily held on behalf of public and client accounts.
NYSE
FMR LLC and Abigail P. Johnson report a 5.1% beneficial ownership of Teva Pharmaceutical Industries Ltd. common stock.
NYSE
Phoenix Financial Ltd. has reported a 5% beneficial ownership stake in Teva Pharmaceutical Industries Ltd., holding over 57 million ordinary shares.
NYSE
Menora Mivtachim Holdings Ltd. has disclosed a 5% beneficial ownership stake in Teva Pharmaceutical Industries Ltd., totaling 57,395,173 ordinary shares.
NYSE
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 7.2% Passive Stake in Teva Pharmaceutical Industries Ltd.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.2% of Teva Pharmaceutical Industries Ltd.'s common stock as of December 31, 2024.